载药微球支气管动脉栓塞化疗治疗晚期非小细胞肺癌10例  

Drug-eluting beads bronchial arterial chemoembolization for the treatment of advanced non-small cell lung cancer: curative efficacy in 10 patients

作　　者：郭立文 郑家平 郝伟远 曾晖 章浙伟 邵国良[1] GUO Liwen;ZHENG Jiaping;HAO Weiyuan;ZENG Hui;ZHANG Zhewei;SHAO Guoliang(Department of Intervention,Zhejiang Provincial Cancer Hospital,Institute of Oncology and Basic Medicine,Chinese Academy of Sciences,Affiliated Cancer Hospital,University of Chinese Academy of Sciences,Hangzhou,Zhejiang Province 310022,China)

机构地区：[1]中国科学院肿瘤与基础医学研究所,中国科学院大学附属肿瘤医院/浙江省肿瘤医院介入治疗科,杭州310022

出　　处：《介入放射学杂志》2021年第1期24-28,共5页Journal of Interventional Radiology

基　　金：浙江省医药卫生科技计划项目(2018RC023、2020KY064)。

摘　　要：目的研究载药微球支气管动脉栓塞化疗(DEB-BACE)在晚期非小细胞肺癌(NSCLC)中的疗效和安全性。方法回顾性分析2016年4月至2019年4月行DEB-BACE的NSCLC患者临床资料。结果共入选10例患者纳入分析,平均随访时间15.2个月(3~24个月),手术的技术成功率100%,首次DEB-BACE治疗6周后疗效评估客观缓解率(ORR)为20%,疾病控制率(DCR)为90%;随访12周时,ORR为40%,DCR为60%。中位疾病无进展生存(mPFS)是4个月(3-24个月),中位生存(mOS)是15个月(3~24个月),最常见的不良事件为恶心(n=8)、呕吐(n=8)、咳嗽(n=7)和白细胞数降低(n=7),大多数不良事件为轻中度(1/2级),经对症处理后恢复,所有患者未出现介入栓塞相关的严重不良反应。结论 DEB-BACE治疗晚期NSCLC疗效良好,具有较高的安全性。Objective To evaluate the curative efficacy and safety of drug-eluting beads bronchial arterial chemoembolization(DEB-BACE) in treating advanced non-small cell lung cancer(NSCLC). Methods The clinical data of 10 patients with NSCLC,who were admitted to the Zhejiang Provincial Cancer Hospital of China during the period from April 2016 to April 2019 to receive DEB-BACE treatment,were retrospectively analyzed. Results A total of 10 patients were enrolled in this study. The average follow-up time was 15.2 months(3-24 months). The technical success rate of intervention was 100%. Six weeks after the initial DEBBACE treatment,the objective response rate(ORR) was 40% and the disease control rate(DCR) was 60%.The median progress-free survival(PFS) was 4 months(3-24 months),and the median overall survival(OS)was 15 months(3-24 months). The most common adverse events included nausea(n=8),vomiting(n=8),coughing(n=7) and leukopenia(n=7). Most adverse events were mild to moderate(grade Ⅰ-Ⅱ),which recovered after symptomatic treatment. No embolization-related serious adverse reactions occurred in all patients.Conclusion For the treatment of advanced NSCLC,DEB-BACE has excellent curative effect and higher safety.(J Intervent Radiol,2021,30: 24-28)

关 键 词：非小细胞肺癌 支气管动脉栓塞化疗 载药微球 

分 类 号：R734[医药卫生—肿瘤]